

Supplementary Material

Major Differences in Glycosylation and Fucosyltransferase Expression in Low-Grade Versus High-Grade Bladder Cancer Cell Lines

Bernadette Ezeabikwa^{1,*}, Nandini Mondal^{2,*}, Aristotelis Antonopoulos³, Stuart M. Haslam³, Yasuyuki Matsumoto², Miguel Martin-Caraballo⁴, Sylvain Lehoux^{2,5}, Msano Mandalasi^{1,6}, Ali Ishaque¹, Jamie Heimborg-Molinaro², Richard D. Cummings^{2,7} and Anthony K. Nyame^{1,7}

¹Department of Natural Sciences, University of Maryland Eastern Shore, Princess Anne, MD

²Department of Surgery, Beth Israel Deaconess Medical Center - Harvard Medical School, Boston, MA

³Department of Life Sciences, Imperial College London SW7 2AZ, UK

⁴Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland Eastern Shore, Princess Anne, MD

⁵Current address: Novab Inc., Atlanta, GA

⁶Current address: Department of Biochemistry and Molecular Biology, University of Georgia, Athens, GA

*These individuals should be considered as co-first authors

⁷Corresponding Authors:

Dr. Anthony Kwame Nyame
Department of Natural Sciences
University of Maryland Eastern Shore
Princess Anne, MD 21853
Tel: 1-410-603-8999
aknyame@gmail.com

Dr. Richard D. Cummings
Department of Surgery
Beth Israel Deaconess Medical Center
Harvard Medical School
CLS 11087 - 3 Blackfan Circle
Boston, MA 02115
Tel: 1-617-735-4643
rcummin1@bidmc.harvard.edu

Running title: Differential fucosylation in low- and high-grade bladder cancer

Keywords: Bladder cancer, Glycan marker, Lewis-X, Fucosyltransferase, Glycomics

Supplementary material information: This manuscript contains Supplementary Table I and Supplementary Figures 1-8

Supplementary Figure Legends

Supplementary Figure 1. Immunofluorescence analysis of bladder cancer cell lines

for the presence of Lewis antigens. (A) RT4, J82COT, T24, TCCSUP and HL-60 control

cells were incubated with anti-Le^x IgG mAb F8A1.1 and bound antibodies were detected by incubation with Alexa-488 conjugated goat anti-mouse IgG followed by fluorescence microscopy imaging. Panels **a** and **c**: phase contrast images, Panels **b** and **d**:

fluorescence images; Panels **a** and **b**: control incubation conducted without mAb F8A1.1;

Panels **c** and **d**: incubation conducted with mAb F8A1.1. **(B)** RT4, T24, and HL-60 control

cells were incubated with anti-sialyl-Le^x IgM mAb HECA452 and bound antibodies were detected with Alexa-488 conjugated goat anti-rat IgM followed by imaging by fluorescence microscopy. Panels **a** and **c**: phase contrast images; Panels **b** and **d**: fluorescence

images; Panels **a** and **b**: incubation with HECA452; Panels **c** and **d**: mock incubation

lacking HECA452. **(C)** Western blot analysis of Le^x-bearing glycoproteins

immunoprecipitated from extracts of J82COT, RT4, and T24 cells using mAb F8A1.1

(lanes indicated by +). Mock immunoprecipitations were carried out by omitting mAb

F8A1.1 from the immunoprecipitation complex (lanes indicated by -).

Supplementary Figure 2 (related to Figure 2, panel A). Binding of HECA452 mAb to

bladder cancer cells. (A) Flow cytometry histograms showing staining of (*left*) normal

bladder epithelial cells A/T/N, (*middle*) low-grade bladder cancer cells RT4, and (*right*)

high-grade bladder cancer cells T24 with either isotype control (open histograms) or mAb

HECA452 (grey histograms). **(B)** Flow cytometry histograms showing staining of (*left*) low-

grade bladder cancer cell line 5637 and (*right*) low-grade bladder cancer cell line SW780

with either isotype control (light grey histograms) or mAb HECA452 (dark grey histograms).

Supplementary Figure 3 (related to Figure 2, panel B). Expression of sialofucosylated lactosaminyl glycans by bladder cancer cells. Flow cytometry histograms showing staining of **(A)** normal bladder epithelial cells A/T/N, **(B)** low-grade bladder cancer cells RT4, and **(C)** high-grade bladder cancer cells T24 with plant lectins, *from left to right*, AAL, MAL-I, MAL-II, SNA, and PHA-L. Open histograms present staining with secondary detection reagent alone (Streptavidin-Alexa488) and grey histograms present staining with respective plant lectin. **(D)** Flow cytometry histograms showing staining of low-grade bladder cancer cell lines 5637 (*left*) and SW780 (*right*) with respectively from top to bottom, secondary detection reagent alone, AAL, MAL-I, MAL-II, and PHA-L lectins. **(E)** Flow cytometry histograms showing staining of low-grade bladder cancer cell lines 5637 (*left*) and SW780 (*right*) with secondary detection reagent alone (*top histogram*) and SNA lectin (*bottom histogram*).

Supplementary Figure 4. Immunofluorescence analysis to assess binding of plant lectins on the membrane of bladder cancer cells. A/T/N, RT4, J82COT, T24, and TCCSUP cells were incubated with biotinylated lectins detected with Alexa-488-conjugated streptavidin. **(A)** AAL staining. +Fucose indicates addition of fucose to confirm lectin binding specificity. –AAL indicates streptavidin alone control. **(B)** L-PHA staining. +GalNAc indicates addition of GalNAc to confirm L-PHA binding specificity. For **A** and **B**, **Panels a, c, e:** phase contrast images, **Panels b, d, f:** fluorescence images. **(C)** Western blot analysis of lysates of A/T/N, RT4, J82COT, T24, and TCCSUP using AAL lectin as probe.

Identical amount of cell lysate protein was analyzed for each cell line. **(Left panel)** AAL blot of untreated cell lysates. –Fucose: free fucose was not added during blotting. +Fucose: free fucose was added during blotting to confirm AAL binding specificity. **(Middle panel)** AAL blot of cell lysates either untreated (-) or treated with PNGase F (+). **(Right panel)** AAL blot without (-NaOH) or with (+NaOH) β -elimination of O-glycans using NaOH.

Supplementary Figure 5. MALDI-TOF MS spectrum of permethylated N-glycans derived from **(A)** A/T/N, **(B)** T24, and **(C)** RT4 cell lines. Permethylated N-glycans were eluted at the 50% acetonitrile fraction (**Materials and Methods**). Main structures are depicted. Structures above a bracket have not had their location unequivocally defined. Putative structures are based on composition, tandem MS and knowledge of biosynthetic pathways. All molecular ions are $[M+Na]^+$.

Supplementary Figure 6. MALDI-TOF/TOF MS/MS spectra of the molecular ions at **(A)** m/z 3316 and **(B)** m/z 3490 selected from A/T/N cell lines (**Supplementary Figure 5A**). Structures outside a bracket have not had their location unequivocally defined. Putative structures are based on composition, tandem MS and knowledge of biosynthetic pathways. All molecular ions are $[M+Na]^+$. Horizontal blue dashed lines with arrowheads indicate the losses of the corresponding structures from the molecular ions. Fragment ion peaks in green colour correspond to losses of two LacNAc repeats having attached various fucose residues, from the molecular ion. In **(B)** fragment ion peak marked with an asterisk (*) corresponds to a contamination fragment ion from the molecular ion at m/z 3503.

Supplementary Figure 7. MALDI-TOF/TOF MS/MS spectra of the molecular ions at **(A)** m/z 5085, **(B)** m/z 5259, **(C)** m/z 5360, **(D)** m/z 5708, **(E)** m/z 5883 and **(F)** m/z 6332 selected from RT4 cell lines (**Supplementary Figure 5c**). Structures above/outside a bracket have not had their location unequivocally defined. Putative structures are based on composition, tandem MS and knowledge of biosynthetic pathways. All molecular ions are $[M+Na]^+$. Horizontal blue dashed lines with arrowheads indicate the losses of the corresponding structures from the molecular ions. Fragment ion peaks in green, yellow and red colours correspond to losses of two, three and four LacNAc repeats having attached various fucose residues, from the molecular ion respectively.

Supplementary Figure 8. Expression of fucosyltransferase genes in TCCSUP and J82COT cells. All gene expression is calculated using the ΔC_T method and expressed as per mille (‰) of GAPDH expression. **(A)** Bar plots present gene expression of FUTs 1-7. **(B)** Bar plots present gene expression of FUTs 8-11. Data are presented as Mean \pm SD of technical quadruplicates. Statistics: *t*-test was performed for each gene comparing the means of the two cell lines. Statistical significance was determined using Holm-Sidak method. $P < 0.05$ is considered statistically significant difference. **(C)** Sequences of the primers used for gene expression analysis. All primer sequences were kindly provided by Dr. Kelley Moremen (Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia).

Supplementary Table I


Supplemental Table 1. List of qRT-PCR primers used to amplify glycosyltransferase transcripts

Gene	Forward Primer (5'-3')	Reverse Primer (5'-3')	Source
<i>FUT1</i>	AGCAACGGCATGGAGTGGTGTA	AAGCCGAAGGTGCCAATGGTCA	Origene
<i>FUT2</i>	CTACCACCTGAACGACTGGATG	AGGGTGAACCTCCTGGAGGATCT	Origene
<i>FUT3</i>	GCCGACCGCAAGGTGTAC	TGACTTAGGGTTGGACATGATATCC	(Higai <i>et al</i> , 2006)
<i>FUT4</i>	GGGTTTGGATGAACTTCGAGTCG	GGTAGCCATAAGGCACAAAGACG	(Mondal <i>et al</i> , 2018)
<i>FUT5</i>	ACCTGAGCTACTTTCCTACTGGCG	TCAGGTGAACCAAGCCGCTATG	(Mondal <i>et al</i> , 2018)
<i>FUT6</i>	CCGACTACATCACCGAGAAGCT	GAACCTCTCGTAGTTGCTTCTGC	(Mondal <i>et al</i> , 2018)
<i>FUT7</i>	GAATGAGAGCCGATACCAACGC	TAGCGGTACAGATGGCACAGA	(Mondal <i>et al</i> , 2018)
<i>FUT8</i>	ATCCTGATGCCTCTGCAAC	GGGTTGGTGAGCATAAATGG	(Bernardi, <i>et al</i> 2013)
<i>FUT9</i>	TCCCATGCAGTTCTGATCCAT	GAAGGGTGGCCTAGCTTGCT	(Higai <i>et al</i> , 2006)
<i>FUT10</i>	CTAACCAGCGACTTCTGACAGC	CCCATCTTTTGGGTGGTAAGCC	Origene
<i>FUT11</i>	ACACCTGGCTTTGGCAATGTGG	GTGGATCATGGCAGTGAGAGCT	Origene
<i>ST3Gal I</i>	AAGAGGACCCTGAAAGTGCTC	CTCCAGGACCATCTGCTTGG	(Silva <i>et al</i> , 2017)
<i>ST3Gal3</i>	GCCTGCTGAATTAGCCACCAA	GCCCACTTGCGAAAGGAGT	(Silva <i>et al</i> , 2017)
<i>ST3Gal4</i>	CTTCTGCGGCTTGAGGATTA	CTCACTCCCCTTGGTCCCATA	(Silva <i>et al</i> , 2017)
<i>ST3Gal6</i>	ACTGCATTGCATATTATGGGGAA	TGGCTTTGATAAACAAGGCTGG	(Mondal <i>et al.</i> , 2018)
<i>ST6Gal I</i>	CTGAATGGGAGGGTTATCTGCC	ACCTCAGGACTGCGTCATGATC	(Silva <i>et al</i> , 2017)
<i>ST6Gal2</i>	ACGCTGCTGATTGACTCTTCT	CACATACTGGCACTCATCTAA	(Ma <i>et al</i> , 2014)
<i>ST6GALNACI</i>	CTCTCTTCTGGACTCCAGACA	AAGCGTGTACGACCTTCTGCA	Origene
<i>ST6GalNAcII</i>	ACTTCCGTGGCCTGTTCAATC	GGCGATGACTTGGTGAGAGAG	(Silva <i>et al</i> , 2017)
<i>ST6GALNAC3</i>	TACGTGACCACAGAGAAGCGCA	CGTGAATGCCATAACAGGCGTC	Origene
<i>ST6GALNAC5</i>	GATTACTCGCCACAAGATGCTGC	GATCCTGTACAGAGCTCCAGT	Origene
<i>ST6GALNAC6</i>	TGAGGTCTTCCATTACGGCTCC	CTGCTGACAATCACACACTGGTG	Origene
<i>B4GalT1</i>	GTATTTTGGAGGTGTCTCTGCTC	GGGCGAGATATAGACATGCCTC	(Mondal <i>et al</i> , 2018)
<i>B4GalT2</i>	GACCGCGACAAGCATAACGAAC	AGACACCTCCAAGACCTGGTAC	Origene
<i>B4GalT3</i>	TCCTCAAGGTCTGCCCTACTGT	ATTCCGCTCCACAATCTCTGCC	Origene
<i>B4GalT4</i>	CTCTGACTAATGAAGCATCCACG	CTGCCTGTACCTCTTCCAAAGTG	Origene
<i>B4GalT5</i>	GAAGATGACGACCTCTGGAACAG	GCCGTTCTTTTACTTCTCAGC	Origene
<i>B4GalT6</i>	CTCATTCCTTTCCGTAATCGCCA	GCCCACATTGAAAAGCATCGCAC	Origene
<i>B4GalT7</i>	TGCTCAACCAGGTGGACCACTT	AGGTCAACGTCGTGCATGGCAA	Origene
<i>B3GALT1</i>	CCTCATCAGCACCCTCACAAG	TGGCTCTCTTGCTCCACCATCT	Origene
<i>B3GALT2</i>	GTGTTCAATCACTGGCGAGTCTC	TTGCTGCGTTGGCACAGGCATT	Origene
<i>B3GALT4</i>	TCCTACCGCAACCTCACCTAA	TCGCAAGACCAGCTCTGATACC	Origene
<i>B3GALT5</i>	AGCGGAAACGAAAAGAGGTGGAC	CCTGAGGACAAAAGCGATGGAC	Origene
<i>B3GALT6</i>	ACCAGTACCTGGTGACGCACAA	GACCAGTCGTACACGTAGGACA	Origene
<i>GCNT1</i>	AACCCCTTAGTAAAGAAGAGGCG	AGCAGCCTGTCAAGCATTTCA	(Silva <i>et al</i> , 2017)
<i>GCNT3-For</i>	CACCAGAGACTGTGAGCACTTC	CATACACAGCTCGCAGTAGCCT	Origene
<i>GCNT4-For</i>	CTCTCCTGATGAGCACTTTTGGG	CCACTTGACAAGGCGAGTCTTAC	Origene
<i>MGAT1</i>	CCTATGACCGAGATTTCTCTCGC	TGAAGCTGTCCCTGCCCGTATA	(Mondal <i>et al</i> , 2018)
<i>GCNT2-For</i>	TCCTGGTCCAAGGACACCTACA	CTGAGGTTTCCAGTCCAGGATG	Origene
<i>GAPDH</i>	CAGCCTCAAGATCATCAGC	ACAGTCTTCTGGGTGGCA	(Mondal <i>et al</i> , 2018)
<i>B-Actin</i>	CACCATTGGCAATGAGCGGTTTC	AGGTCTTTGCGGATGTCCACGT	(Mondal <i>et al</i> , 2018)



References for Supplementary Table I

- Bernardi, C., Soffientini, U., Piacente, F., & Tonetti, M. G. (2013). Effects of microRNAs on fucosyltransferase 8 (FUT8) expression in hepatocarcinoma cells. *PloS one*, 8(10), e76540-e76540. doi:10.1371/journal.pone.0076540
- Higai, K., Ishihara, S., & Matsumoto, K. (2006). NF κ B-p65 Dependent Transcriptional Regulation of Glycosyltransferases in Human Colon Adenocarcinoma HT-29 by Stimulation with Tumor Necrosis Factor α . *Biological and Pharmaceutical Bulletin*, 29(12), 2372-2377. doi:10.1248/bpb.29.2372
- Mondal, N., Dykstra, B., Lee, J., Ashline, D. J., Reinhold, V. N., Rossi, D. J., & Sackstein, R. (2018). Distinct human α (1,3)-fucosyltransferases drive Lewis-X/sialyl Lewis-X assembly in human cells. *Journal of Biological Chemistry*, 293(19), 7300-7314. doi:10.1074/jbc.RA117.000775
- Silva, M., Fung, R. K. F., Donnelly, C. B., Videira, P. A., & Sackstein, R. (2017). Cell-Specific Variation in E-Selectin Ligand Expression among Human Peripheral Blood Mononuclear Cells: Implications for Immunosurveillance and Pathobiology. *Journal of immunology (Baltimore, Md. : 1950)*, 198(9), 3576-3587. doi:10.4049/jimmunol.1601636




Supplementary figure 1




Supplementary figure 2



Supplementary figure 3




Supplementary figure 4




Supplementary figure 5

5A




Supplementary figure 5

5B




Supplementary figure 5

5C




Supplementary figure 6

A




B




Supplementary figure 7


A



B







C





▼ Fuc ● Gal ■ GlcNAc
▬ 2 LacNAcs ▬ 3 LacNAcs

Supplementary figure 7



Supplementary figure 8



C

Gene	Forward Primer (5'-3')	Reverse Primer (5'-3')
<i>FUT1</i>	GGCCTTCCTGCTAGTCTGTG	GCCATGTGGAAAGCTGTCTT
<i>FUT2</i>	GATTCAAGCCATGTGGGAGT	GTCCCAGTGCCTTTGATGTT
<i>FUT3</i>	CGCTGGATCTGGTTCAACTT	GTATCTGTCCAGGGCTTCCA
<i>FUT4</i>	TGGCCCGCTACAAGTTCTAC	GCCAGAGCTTCTCGGTGATA
<i>FUT5</i>	ACATCACTGCCGACTCCAGT	CATGATATCCCAGTGGTGCA
<i>FUT6</i>	CTGCTGATGGCTGTGTGTTT	GGGTACACAGTGGGATCGTC
<i>FUT7</i>	GTGCATGTGGATGACTTTGG	GCTCTCATTCATGCCAGTGA
<i>FUT8</i>	GGTCGAGCTTCCCATTGTAG	GCGAGGTCTTCTGGTACAGC
<i>FUT9</i>	CTTACCGCCGTGATTCAGAT	AAACACGAAGGGATTTGTGC
<i>FUT10</i>	TATGTTTCGCGAGCTGATGAC	TGAGGGAGGTCTTTGTTTCG
<i>FUT11</i>	AGTCTGAAGCATCGGGAGTG	TCGAAGCCGTTGAGGTAGTT